Advertisement

The Diet for Galactosemia

Chapter
  • 1.8k Downloads

Abstract

  • Classical galactosemia can result in life-threatening complications including failure to thrive, hepatocellular damage, and E. coli sepsis in untreated infants.

  • Initiation of a soy formula or a lactose-free medical food within the first few days of life can mitigate these complications.

  • Patients with classical galactosemia are at increased risk for developmental delay, speech problems, and neurological complications, even with lifelong dietary treatment.

  • Dairy products are the primary source of dietary galactose.

  • Galactose is produced endogenously and accounts for a greater contribution to the total galactose pool than the small amounts of galactose found in plant-based foods.

Keywords

Bone Mineral Density Dietary Reference Intake Elemental Formula Lactose Content Premature Ovarian Insufficiency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Acosta PB. Nutrition management of patients with inherited disorders of galactose metabolism. In: Acosta PB, editor. Nutrition management of patients with inherited metabolic disorders. Sudbury, Massachusetts: Jones and Bartlett Publishers, LLC; 2010. p. 476.Google Scholar
  2. 2.
    Calderon FR, et al. Mutation database for the galactose-1-phosphate uridyltransferase (GALT) gene. Hum Mutat. 2007;28(10):939–43.PubMedCrossRefGoogle Scholar
  3. 3.
    Bosch AM, et al. Identification of novel mutations in classical galactosemia. Hum Mutat. 2005;25(5):502.PubMedCrossRefGoogle Scholar
  4. 4.
    Tyfield L, et al. Classical galactosemia and mutations at the galactose-1-phosphate uridyl transferase (GALT) gene. Hum Mutat. 1999;13(6):417–30.PubMedCrossRefGoogle Scholar
  5. 5.
    Shils ME, Shike M. Modern nutrition in health and disease. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. xxv, 2069 p.Google Scholar
  6. 6.
    Waggoner DD, Buist NR, Donnell GN. Long-term prognosis in galactosaemia: results of a survey of 350 cases. J Inherit Metab Dis. 1990;13(6):802–18.PubMedCrossRefGoogle Scholar
  7. 7.
    Coss KP, et al. N-glycan abnormalities in children with galactosemia. J Proteome Res. 2014;13(2):385–94.Google Scholar
  8. 8.
    Gross KC, Acosta PB. Fruits and vegetables are a source of galactose: Implications in planning the diets of patients with galactosemia. J Inher Metab Dis. 1991;14:253–8.Google Scholar
  9. 9.
    Zlatunich CO, Packman S. Galactosaemia: early treatment with an elemental formula. J Inherit Metab Dis. 2005;28(2):163–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Vandenplas Y, et al. Soy infant formula: is it that bad? Acta Paediatr. 2011;100(2):162–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Agostoni C, et al. Soy protein infant formulae and follow-on formulae: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2006;42(4):352–61.PubMedCrossRefGoogle Scholar
  12. 12.
    Ficicioglu C, et al. Effect of galactose free formula on galactose-1-phosphate in two infants with classical galactosemia. Eur J Pediatr. 2008;167(5):595–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Turck D. Soy protein for infant feeding: what do we know? Curr Opin Clin Nutr Metab Care. 2007;10(3):360–5.PubMedCrossRefGoogle Scholar
  14. 14.
    WHO Technical Report Series: evaluation of certain veterinary drug residues in foods. World Health Organization, 1999. http://www.who.int/foodsafety/chem/jecfa/publications/reports/en/index.html (Accessed June 2014).
  15. 15.
    Palmieri M, et al. Urine and plasma galactitol in patients with galactose-1-phosphate uridyltransferase deficiency galactosemia. Metabolism. 1999;48(10):1294–302.PubMedCrossRefGoogle Scholar
  16. 16.
    Bhatia J, Greer F, American Academy of Pediatrics Committee on Nutrition. Use of soy protein-based formulas in infant feeding. Pediatrics. 2008;121(5):1062–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Mendez MA, Anthony MS, Arab L. Soy-based formulae and infant growth and development: a review. J Nutr. 2002;132(8):2127–30.PubMedGoogle Scholar
  18. 18.
    Portnoi PA, MacDonald A. Determination of the lactose and galactose content of cheese for use in the galactosaemia diet. J Hum Nutr Diet. 2009;22(5):400–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Van Calcar SC, et al. Galactose content of legumes, caseinates, and some hard cheeses: implications for diet treatment of classic galactosemia. J Agric Food Chem. 2014;62(6):1397–402.PubMedCrossRefGoogle Scholar
  20. 20.
    Southward CR. Casein products: chemical processes in New Zealand. New Zealand: New Zealand Dairy Research Institute; 1998. p. 1–13.Google Scholar
  21. 21.
    Wright EM, Martín MG, Turk E. Intestinal absorption in health and disease – sugars. Best Pract Res Clin Gastroenterol. 2003;17(6):943–56.PubMedCrossRefGoogle Scholar
  22. 22.
    Upreti VV, et al. Determination of endogenous glycosaminoglycans derived disaccharides in human plasma by HPLC: validation and application in a clinical study. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;831(1–2):156–62.PubMedCrossRefGoogle Scholar
  23. 23.
    Kim HO, Hartnett C, Scaman CH. Free galactose content in selected fresh fruits and vegetables and soy beverages. J Agric Food Chem. 2007;55(20):8133–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Hartnett C, Kim HO, Scaman CH. Effect of processing on galactose in selected fruits. Can J Diet Pract Res. 2007;68(1):46–50.PubMedCrossRefGoogle Scholar
  25. 25.
    Schadewaldt P, et al. Age dependence of endogenous galactose formation in Q188R homozygous galactosemic patients. Mol Genet Metab. 2004;81(1):31–44.PubMedCrossRefGoogle Scholar
  26. 26.
    Berry GT, et al. Endogenous synthesis of galactose in normal men and patients with hereditary galactosaemia. Lancet. 1995;346(8982):1073–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Berry GT, et al. The rate of de novo galactose synthesis in patients with galactose-1-phosphate uridyltransferase deficiency. Mol Genet Metab. 2004;81(1):22–30.PubMedCrossRefGoogle Scholar
  28. 28.
    Berry GT, et al. Extended [13C]galactose oxidation studies in patients with galactosemia. Mol Genet Metab. 2004;82(2):130–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Bosch AM, et al. High tolerance for oral galactose in classical galactosaemia: dietary implications. Arch Dis Child. 2004;89(11):1034–6.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Van Calcar SC, et al. A re-evaluation of life-long severe galactose restriction for the nutrition management of classic galactosemia. Mol Genet Metab. 2014;112(3):191–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Panis B, et al. Bone metabolism in galactosemia. Bone. 2004;35(4):982–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Rubio-Gozalbo ME, et al. Bone mineral density in patients with classic galactosaemia. Arch Dis Child. 2002;87(1):57–60.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Gajewska J, et al. Serum markers of bone turnover in children and adolescents with classic galactosemia. Adv Med Sci. 2008;53(2):214–20.PubMedCrossRefGoogle Scholar
  34. 34.
    Kaufman FR, et al. Effect of hypogonadism and deficient calcium intake on bone density in patients with galactosemia. J Pediatr. 1993;123(3):365–70.PubMedCrossRefGoogle Scholar
  35. 35.
    Batey LA, et al. Skeletal health in adult patients with classic galactosemia. Osteoporos Intl. 2013;24(2):501–9.Google Scholar
  36. 36.
    van Erven B, Römers MM, Rubio-Gozalbo ME. Revised proposal for the prevention of low bone mass in patients with classic galactosemia. JIMD Rep. 2014;17:41–6.PubMedCentralPubMedGoogle Scholar
  37. 37.
    Institute of Medicine. In: Ross AC et al., editors. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academies Press; 2011. p. 345–403.Google Scholar
  38. 38.
    Bachrach LK, Sills IN, Section on Endocrinology. Clinical report – bone densitometry in children and adolescents. Pediatrics. 2011;127(1):189–94.PubMedCrossRefGoogle Scholar
  39. 39.
    Pramyothin P, Holick MF. Vitamin D supplementation: guidelines and evidence for subclinical deficiency. Curr Opin Gastroenterol. 2012;28(2):139–50.PubMedCrossRefGoogle Scholar
  40. 40.
    Panis B, van Kroonenburgh MJ, Rubio-Gozalbo ME. Proposal for the prevention of osteoporosis in paediatric patients with classical galactosaemia. J Inherit Metab Dis. 2007;30(6):982.PubMedCrossRefGoogle Scholar
  41. 41.
    Bernstein L, et al. Galactosemia: the diet. Aurora: Children’s Hospital Colorado; 2014.Google Scholar
  42. 42.
    Bernstein L, et al. Galactosemia: school age children. Aurora: Children’s Hospital Colorado; 2014.Google Scholar
  43. 43.
    Bernstein L, et al. Galactosemia: for new parents. Aurora: Children’s Hospital Colorado; 2014.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Clinical Genetics and MetabolismChildren’s Hospital Colorado, University of Colorado Denver – Anschutz Medical CampusAuroraUSA
  2. 2.Department of Molecular and Medical Genetics and Graduate Programs in Human Nutrition, School of MedicineOregon Health and Science UniversityPortlandUSA

Personalised recommendations